Drug Profile
CD 2475 101
Alternative Names: CD-2475-101; CD2475/101Latest Information Update: 17 Jun 2015
Price :
$50
*
At a glance
- Originator Galderma
- Class Antiacnes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 17 Jun 2015 No recent reports of development identified - Phase-II for Acne vulgaris in USA (PO)
- 01 Jan 2012 Galderma completes a Phase-II trial in Acne vulgaris in USA (NCT01320033)
- 14 Oct 2011 Galderma completes enrolment in its phase II trial for Acne vulgaris in USA (NCT01320033)